文献速递免疫规划卫生政策与健康促进

中非共和国12-23月龄儿童五价疫苗系列脱失率及影响因素

Dropout from the pentavalent vaccine series among children aged 12-23 months in the Central African Republic: prevalence, associated factors, and caregiver-reported barriers.
PubMed 文献 · Vaccine · 2026-05-15

在中非共和国全国七个卫生区35个地区开展横断面家庭调查,分析4121名已接种第一剂五价疫苗的12-23月龄儿童。第一剂至第三剂脱失率为34.5%(95%CI: 32.4-36.6),无电视、无出生登记和看护人务农与脱失风险升高相关。主要障碍包括距离接种点远、疫苗缺货和缺乏接种知识。

要点

  • 中非共和国五价疫苗第一至第三剂脱失率达34.5%,需加强后续剂次随访。
  • 无电视、无出生登记和看护人务农与脱失风险升高相关。
  • 距离、缺货、时间限制和知识不足是主要报告的障碍。

核心结论

  • 中非共和国34.5%的儿童在接种第一剂五价疫苗后未完成三剂系列。
  • 需改善随访并调整服务以克服当地障碍,提高全程免疫覆盖率。

研究设计与样本

  • 2023年12月至2024年3月在中非共和国全国七个卫生区35个地区开展横断面家庭调查。
  • 分析4121名已接种第一剂五价疫苗的12-23月龄儿童,使用Stata 17进行调查加权逻辑回归。

主要发现

  • 第一剂至第三剂五价疫苗脱失率为34.5%(95%CI: 32.4-36.6)。
  • 第一剂至第二剂脱失率为17.0%,第二剂至第三剂脱失率为17.5%,第三剂至含麻疹疫苗脱失率为15.8%。
  • 无电视家庭脱失风险aOR为2.98(95%CI: 1.88-4.72),无出生登记aOR为1.56(95%CI: 1.26-1.94),看护人务农aOR为3.45(95%CI: 1.85-6.44)。

关键数值与推荐

  • 主要报告未接种原因:距离接种点远30.9%、疫苗缺货14.0%、看护人时间限制29.7%、家庭问题10.8%、缺乏接种知识27.3%、害怕副作用10.4%、不信任疫苗2.9%。

临床怎么用

  • 针对无电视、无出生登记和务农家庭的儿童加强后续剂次随访。
  • 根据当地障碍调整服务,如缩短距离、确保疫苗供应和加强接种知识宣教。

局限性

  • 横断面设计无法确定因果关系。
  • 接种状态主要依赖家庭记录,缺失时使用卫生机构数据或看护人回忆,可能存在回忆偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Routine childhood immunization in the Central African Republic (CAR) is inconsistent due to reasons including political instability and service disruptions. This study assessed dropout between the first and third pentavalent doses among children aged 12-23 months who had received Penta 1, identified associated risk factors, and explored caregiver-reported barriers. Additional dropout indicators within this cohort-specifically from Penta 1 to Penta2, from Penta2 to Penta 3, and from Penta 3 to measles-were also examined to support contextual interpretation. METHODS: We conducted a cross-sectional household survey from December 2023 to March 2024, based on a nationally representative sample covering all seven health regions and 35 districts of the CAR. This secondary analysis focused on dropout between key vaccine doses among children aged 12-23 months and was conducted using Stata 17. Data were collected through structured interviews with caregivers, with vaccination status primarily verified using home-based records; when unavailable, health facility data or caregiver recall were used. Survey-weighted logistic regression models were used to identify factors associated with vaccine dropout. Reasons for non-vaccination were analyzed thematically using the adapted WHO BeSD framework. RESULTS: Among 4121 children aged 12-23 months who had received Penta 1, the national prevalence of dropout between the first and third doses of the pentavalent vaccine was 34.5% (95% CI: 32.4-36.6). Additionally, among these children, we observed 17.0% dropout from Penta 1 to Penta2, 17.5% from Penta2 to Penta 3, and 15.8% from Penta 3 to the measles-containing vaccine. Higher odds of dropout between Penta 1 and Penta 3 were associated with households lacking television (aOR: 2.98; 95% CI:1.88-4.72), absence of birth registration (aOR:1.56; 95% CI:1.26-1.94) and caregivers engaged in agricultural activities (aOR:3.45; 95% CI:1.85-6.44). Primary reported reasons for non-vaccination included access barriers such as distance to the vaccination site (30.9%) and vaccine stockouts (14.0%), contextual and household challenges like caregiver time constraints (29.7%) and family-related problems (10.8%), information gaps including lack of knowledge about the vaccination schedule (27.3%), and motivational concerns such as fear of side effects (10.4%) and distrust in vaccines (2.9%). CONCLUSION: In the CAR, 34.5% of children who receive the first pentavalent dose fail to complete the three dose vaccination series. Improving follow-up and adapting services to overcome local barriers is essential to increase rates of complete immunization.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ishoso DK, Fandema E, Hoff NA, et al. Dropout from the pentavalent vaccine series among children aged 12-23 months in the Central African Republic: prevalence, associated factors, and caregiver-reported barriers. Vaccine. 2026. PMID: 42140089. doi:10.1016/j.vaccine.2026.128700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。